Search Results
FDA-Approved Agents for the Treatment of MCL
Dr. Dean on FDA Approved Drugs for Patients With Relapsed MCL
Dr. Rule on the FDA Approval of Zanubrutinib in MCL
Dr. O'Connor on Recent FDA Approvals in MCL
BTK inhibitors for R/R MCL: current uses and insights from the ViPOR study
MCL: FDA Approval of a Second-Generation BTK Inhibitor
New Agents for Mantle Cell Lymphoma
BeiGene’s Brukinsa (zanubrutinib): a newly approved treatment medicine for mantle cell lymphoma (MCL
Rebooting the BTK Inhibitor Sequence in MCL
Selecting BTK inhibitors for patients with MCL
Optimizing Treatment Pathways in CLL and MCL: Evaluating and Applying Recent Data on BTK Inhibitors
Current treatment options and emerging strategies in MCL